Less Toxic Cancer Therapeutic

The Amplyx oncology program has created a novel taxane that does not exhibit peripheral neuropathy (sensitivity to touch) in an animal model. The Amplyx compound was as effective as paclitaxel in slowing the growth of tumors in a xenograft model of breast cancer. Peripheral neuropathy is a common, dose-limiting side effect of all marketed taxanes. Reducing this side effect should allow more patients to comply with optimal therapeutic regimens and enable better therapeutic outcomes.

Improved Efficacy Against Drug Resistant and Emerging Fungal Pathogens

Our antifungal program employs novel chemistry to rapidly synthesize and test compounds which can specifically inhibit new antifungal targets wthout the toxic side effects produced by current antifungal therapeutics.

Less Toxic HIV Protease Inhibitor

One of our lead compounds is a protease inhibitor for HIV/AIDS. Existing protease inhibitors are metabolized by liver enzymes and cause a number of toxic side effects including high cholesterol and disfigurement from changes in body fat, and onset or worsening of diabetes. With the emergence of an aging HIV positive population, the need for a therapeutic that can be administered with statins, antifungals, and other drugs is increasing.